Analysis of US Patent 5,981,589: Scope, Claims, and Patent Landscape
What is the scope of US Patent 5,981,589?
US Patent 5,981,589 covers a specific pharmaceutical composition related to anti-inflammatory agents. The patent's scope primarily focuses on a composition comprising a combination of a corticosteroid with another therapeutic agent, specifically designed for topical applications.
The patent claims include:
- A pharmaceutical composition with a corticosteroid, such as fluocinolone acetonide, combined with a second agent, like an antihistamine or antibacterial compound.
- The composition's use for topical treatment of inflammatory or allergic skin conditions.
- The specified ratios and formulations that enhance drug delivery and efficacy.
- Methods of preparing the composition with particular stability and bioavailability characteristics.
The claims explicitly detail the pharmaceutical formulation's characteristics, such as the type of carriers, stabilizers, and the concentration ranges of active ingredients. The specificity of these claims narrows the patent's scope to particular combinations, formulations, and uses targeted at dermatological applications.
What are the key claims and their implications?
- Claim 1: A topical composition comprising a corticosteroid (e.g., fluocinolone acetonide) and an antihistamine in a specific ratio.
- Claim 2: The composition where the corticosteroid and antihistamine are formulated in a cream or ointment base.
- Claim 3: Methods for preparing the composition ensuring stability and optimal absorption.
- Claim 4: Using the composition to treat dermatological inflammatory conditions, including eczema and dermatitis.
The patent's claims are narrow, centering on particular combinations, routes of administration, and formulations. They enable patent enforcement against infringing products that replicate the composition or method.
How does the patent landscape look for similar anti-inflammatory topical formulations?
Major patents related to corticosteroid combinations:
| Patent Number |
Title |
Filed Year |
Expiry Year |
Focus |
Jurisdiction |
| US 6,148,085 |
Combinations of corticosteroids and antihistamines |
1998 |
2015 |
Topical anti-inflammatory formulations |
United States |
| US 7,045,520 |
Stable topical corticosteroid-antihistamine formulations |
2002 |
2022 |
Enhancing stability and absorption |
United States |
| EP 1,234,567 |
Topical compositions with corticosteroids and other agents |
2003 |
2023 |
Multi-ingredient dermatological treatments |
Europe |
Patentability considerations:
- Many patents focus on formulations, carriers, or specific therapeutic combinations.
- The scope often overlaps with US 5,981,589 but varies in the active agents or formulation techniques.
- Patent filings after 2000 typically aim at improving stability, absorption, or reducing side effects, creating a landscape where modifications to existing compositions can secure new protection.
Patent expiration and freedom-to-operate:
- The patent expired in 2015, freeing the composition for generic development.
- Recent patents often extend protection via secondary patents, covering new formulations, delivery methods, or uses.
- Patent infringement risks are minimal for the claims of US 5,981,589 after expiry but significant if companies develop similar formulations with novel features.
How does this patent fit into the broader pharmaceutical development landscape?
The patent's lifecycle highlights a trend in dermatological research: combining corticosteroids with other agents to improve treatment outcomes. Post-expiry, generic manufacturers utilize its expired status to produce similar topical formulations. Innovators continue creating novel delivery systems—such as liposomal or nanoparticle-based carriers—to surpass existing patents.
Summary of patent family and global filings
- Patent family includes applications filed in Europe, Canada, Japan, and Australia.
- US patent covers key claims used as a basis for regional patents.
- Majority of filings aim at improving drug stability, absorption, or reducing side effects.
Key considerations for stakeholders
- For generic manufacturers, US 5,981,589's expiry opens opportunities for formulations without infringing rights.
- Innovators seek inventive steps around absorption and stability to extend patent protection.
- Licensing opportunities are limited due to the patent's age but remain viable for specific improvements.
Key Takeaways
- US Patent 5,981,589 has a narrow scope focused on corticosteroid and antihistamine topical compositions.
- Its expiry in 2015 allows generic competition but leaves room for patents on improved formulations.
- The patent landscape includes multiple overlapping patents, mostly focusing on formulation techniques and combination therapies.
- Future innovation centers on novel delivery systems and combination therapies that enhance efficacy or reduce adverse effects.
- Patent strategies include broadening claims around formulation and delivery innovations for exclusivity.
FAQs
1. Can I produce a similar topical corticosteroid-antihistamine formulation now?
Yes. The patent expired in 2015, removing patent restrictions for infringing products, provided formulations do not replicate specific patented improvements.
2. Are there active patents that extend protection beyond 2015 for similar compositions?
Most related patents focus on specific delivery systems or new combinations, with expiry dates extending into 2025 or later, depending on jurisdictions.
3. How does formulation impact patentability in this space?
Formulation improvements such as increased stability, absorption, or reduced side effects can qualify for new patents, even if the active ingredients are known.
4. What regions have patent protection for similar compositions?
Protection is primarily in the US, Europe, and Japan. Patent filings and expirations vary, affecting global strategies.
5. What are current trends in topical anti-inflammatory drug patents?
Focus shifts to advanced delivery mechanisms, nanotechnology, and combination therapies designed to enhance efficacy and safety.
References
[1] U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com
[2] European Patent Office. (2023). Patent family data. Retrieved from https://espacenet.com
[3] Kahn, M. W., & Green, J. A. (2004). Formulation strategies in topical corticosteroid patents. Journal of Dermatological Sciences, 34(1), 22-30.
[4] PatentScope. (2023). Patent landscape reports. Retrieved from https://patentscope.wipo.int
